Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data

Keyphrases

• 6-minute Walk Test (6MWT) 28%
• Agglomerative Hierarchical Clustering 42%
• Balance Index 28%
• Barth Syndrome 100%
• Best Response 14%
• Cardiolipin 14%
• Cardiomyopathy 14%
• Clustering Model 42%
• Disease-modifying Therapy 14%
• Elamipretide 100%
• Fatigue Index 28%
• Functional Response 14%
• Functional Score 28%
• Functional Status 42%
• Growth Abnormality 14%
• Hand-held Dynamometry 14%
• Heart Rate 14%
• Hierarchical Clustering 100%
• High-score 14%
• Median Split 14%
• Mobile Application 14%
• Monolysocardiolipin 14%
• Muscle Strength 14%
• Neutropenia 14%
• Non-responders 14%
• Patient-Reported Outcomes Measurement Information System (PROMIS) 28%
• Physiological Data 14%
• Physiological Measurement 28%
• Physiological Time Series 14%
• Placebo-controlled 14%
• Proof of Concept Study 14%
• Randomized Double-blind 14%
• Rare Genetic Disease 14%
• Respiratory Rate 14%
• Response to Treatment 28%
• Skeletal Growth 14%
• Skeletal Myopathy 14%
• Stand Test 14%
• Symptom Assessment 14%
• Time Series Data 100%
• Wearable Devices 42%

Medicine and Dentistry

• Barth Syndrome 100%
• Body Position 14%
• Cardiolipin 14%
• Cardiomyopathy 14%
• Disease 14%
• Dynamometry 14%
• Elamipretide 100%
• Functional Status 42%
• Genetic Disorder 14%
• Muscle Strength 14%
• Myopathy 14%
• Neutropenia 14%
• Outcome Assessment 28%
• Patient-Reported Outcome 28%
• Placebo 14%
• Six Minute Walk Test 28%
• Symptom Assessment 14%
• Time Series Analysis 100%
• Wearable Sensor 42%

Pharmacology, Toxicology and Pharmaceutical Science

• Barth Syndrome 100%
• Cardiolipin 14%
• Cardiomyopathy 14%
• Disease 14%
• Elamipretide 100%
• Functional Status 42%
• Genetic Disorder 14%
• Myopathy 14%
• Neutropenia 14%
• Placebo 14%
• Symptom 14%